Zhongguancun (000931.SZ): A subsidiary, Beijing Huasuo Lidocaine and Tetracaine Cream, has received a Notice of Approval for Drug Clinical Trial.

Gelonghui, July 21 — Zhongguancun (000931.SZ) announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd. ("Beijing Huasu"), recently received a "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration ("NMPA") for lidocaine and tetracaine cream (strengths: 15g containing 1,050mg lidocaine and 1,050mg tetracaine; 30g containing 2,100mg lidocaine and 2,100mg tetracaine). This product is indicated for local anesthesia of intact skin in adults prior to dermatological procedures such as pulsed laser tattoo removal, laser-assisted hair removal,

Gelonghui FinanceJul 21 15:57

Express News | Zhongguancun: Its subsidiary Beijing Huasu Lidocaine and Tetracaine Cream has received approval for clinical trials.

BreakingsJul 21 15:55

Zhongguancun (000931.SZ): Duoduo Pharmaceutical Co., Ltd., a subsidiary, has received an Acknowledgement of Receipt from the National Medical Products Administration for its Ivabradine Hydrochloride Tablets.

Gelonghui, July 17 — Zhongguancun (000931.SZ) announced that its subsidiary, Duoduo Pharmaceutical Co., Ltd. ("Duoduo Pharma"), recently received an Acceptance Notice issued by the National Medical Products Administration ("NMPA") regarding its marketing authorization application for Ivabradine Hydrochloride Tablets (strength: 5 mg, expressed as C27H36N2O5). Ivabradine Hydrochloride Tablets are indicated for patients with chronic heart failure classified as NYHA Class II–IV with impaired systolic function and sinus rhythm with a heart rate of ≥75 beats per minute, to be used in combination with standard therapy including beta-blockers.

Gelonghui FinanceJul 17 16:18

A-Share Market Movement | The state provides full-chain support for the development and application of innovative drugs, driving related concept stocks higher; Kelun Pharmaceutical rises over 4%.

Gelonghui, July 14 | Innovative pharmaceutical stocks in the A-share market gained strength, with Longshen Rongfa rising more than 13%, HuaRen Health up over 7%, Zhongguancun, Aidikang Pharmaceutical, and Zhongheng Group climbing over 6%, Jiuzhitang and Betta Pharmaceuticals advancing over 5%, and LIFUBIO Pharmaceutical, Gan & Lee Pharmaceuticals, Kelun Pharmaceutical, Kangchen Pharmaceutical, and JenKem Technology all rising over 4%. On the news front, the State Council recently issued the "15th Five-Year Plan for National Health," which proposes comprehensive support across the entire innovation chain for the development and application of innovative drugs and medical devices. It calls for optimizing the review and approval process for innovative and clinically urgently needed medicines, establishing a robust clinical comprehensive evaluation system for innovative drugs, supporting their clinical use, and accelerating the development of cell and gene therapy drugs.

Gelonghui FinanceJul 14 11:13

Zhongguancun: 2026 First-Half Performance Forecast

SZSIJul 11 00:00 · Announcements

Zhongguancun (000931.SZ): Its subsidiary, Shandong Huasu, has received a Notice of Acceptance from the National Medical Products Administration for Metoprolol Succinate Extended-Release Capsules.

Gelonghui, June 21 — Zhongguancun (000931.SZ) announced that its subsidiary, Shandong Huasu Pharmaceutical Co., Ltd. (hereinafter referred to as "Shandong Huasu"), recently received an Acceptance Notice from the National Medical Products Administration (hereinafter referred to as "NMPA") regarding its marketing authorization application for Metoprolol Succinate Extended-Release Capsules (strengths: 95 mg and 47.5 mg, expressed as metoprolol succinate).

Gelonghui FinanceJun 21 15:54